$WGS

GeneDx (WGS) launched a direct-to-family exome testing platform in August 2026, allowing families to initiate clinician-guided testing online. This aligns with updated AAP guidelines and targets underserved pediatric patients. The company projects $475M-$490M revenue for 2026 and $771.4M revenue by 2029, with analysts offering varied outlooks on growth and reimbursement risks.

Simply Wall St reports GeneDx Holdings (WGS) launched an online exome testing pathway on GeneDx.com for U.S. families, enabling clinician-guided tests for children with developmental delay, intellectual disability, or epilepsy. The article cites 30-day return of 18.05% and 90-day return of 91.61%, and discusses valuation versus analyst fair value ($77) and a DCF estimate ($236.93).

GeneDx reported Q2 2026 revenue of $114.4 million, up 11% year over year, with exome and genome revenue of $100.3 million (+17%). Adjusted net income was $0.4 million and adjusted diluted EPS $0.01. Q3 revenue guidance is $122 million to $124 million, and full-year 2026 revenue guidance is $475 million to $490 million.

Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.

GeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of 32% year-over-year • Reported adjusted gross margin (1) of

GeneDx Holdings (formerly Sema4, NASDAQ: WGS) and former officers filed responses in a federal securities class action over alleged overstated capabilities of Centrellis, an AI-molecular and phenotypic data system. The parties settled for about $4.8M to resolve claims of fraud tied to a 2022 GeneDx acquisition valued near $623M. Court filings were submitted July 24, 2026.

Investing.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.

An Alger Small Cap Focus Fund Q2 2026 investor letter discussed GeneDx Holdings Corp. (NASDAQ:WGS), a genomics diagnostics company. The article says WGS closed at $60.65 on July 20, 2026 and that Q1 2026 revenue was $102.3 million, $12 million below expectations, with volumes up 33% YoY. It notes management lowered full-year guidance after revenue missed forecasts.

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against GeneDx Holdings Corp. (NASDAQ: WGS) in the District of Connecticut. The class period runs April 16, 2025 to May 4, 2026, with an Aug. 3, 2026 lead-plaintiff deadline. Allegations center on statements about the viability of GeneDx’s up-to-$51 million acquisition of Fabric Genomics and a May 4, 2026 impairment write-off of $31.3 million.

Levi & Korsinsky announced a securities class action against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged securities fraud. The suit covers purchases between Apr. 16, 2025 and May 4, 2026, alleging misleading statements about the Fabric acquisition’s expected financial and operational benefits. The complaint claims shares traded at inflated prices.